Biodexa Pharmaceuticals PLC Interim Results June 30, 2024

Operational Highlights

Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, announces unaudited interim results for the six months ended June 30, 2024. The Company secured exclusive worldwide licensing of eRapa™, a Phase 3 ready asset targeting Familial Adenomatous Polyposis (“FAP”), along with access to a $17 million grant. Six-month data of eRapa in FAP revealed an 83% non-progression rate and a significant reduction in overall polyp burden, as presented at the Digestive Disease Week scientific meeting in Washington D.C.

Implications

Impact on Individuals

Individuals affected by Familial Adenomatous Polyposis stand to benefit from Biodexa’s efforts in developing innovative treatment options. The promising results of eRapa provide hope for improved outcomes and quality of life for patients living with this genetic disorder. Access to a potential new therapy can significantly impact the lives of those in need.

Global Impact

The introduction of eRapa into the pharmaceutical landscape has the potential to revolutionize the treatment of Familial Adenomatous Polyposis on a global scale. By addressing unmet medical needs through research and development, Biodexa is contributing to advancements in healthcare and bolstering efforts to combat rare diseases worldwide. The Company’s endeavors have far-reaching implications for the future of healthcare and the well-being of populations across the globe.

Conclusion

In conclusion, Biodexa Pharmaceuticals PLC’s interim results for the six months ended June 30, 2024, mark a significant milestone in the field of biopharmaceuticals. The advancements made in developing eRapa as a potential treatment for Familial Adenomatous Polyposis signal a positive shift towards addressing unmet medical needs and improving patient outcomes. As the Company continues its pursuit of innovative therapies, the impact on individuals and the world at large is poised to be profound.